fibroblast growth factor 1

Brain-derived acidic fibroblast growth factor (brain-derived aFGF) (1-11) is a peptide fragment of brain-derived aFGF. Brain-derived aFGF is an angiogenic vascular endothelial cell mitogen produced in bovine brain that has sequence homology to interleukin-1. aFGF (1-11) corresponds to amino acid residues 1-11 of the full length peptide.

Brain-derived basic fibroblast growth factor (1-24) (brain-derived bFGF) is a peptide fragment of brain-derived bFGF. bFGF is a peptide produced in bovine brain that is protective in a rat model of pressure-induced retinal ischemia. bFGF (1-24) corresponds to amino acid residues 1-24 of the full length peptide.

Brain Derived BasicFibroblast Growth Factor(1-24) (FGF basic 1-24) 是一种合成肽，表现出抗细菌和抗HBV 的活性。Brain Derived BasicFibroblast Growth Factor(1-24) 可用于感染性疾病和免疫性疾病的研究。

Brain-derived acidic fibroblast growth factor (102-111) is a peptide fragment of brain-derived acidic fibroblast growth factor (aFGF). aFGF is an angiogenic vascular endothelial cell mitogen produced in bovine brain that has sequence homology to interleukin-1. It also shares sequence homology with the known neuropeptides neuromedin C , bombesin , neuromedin K , substance K , substance P , physalaemin, and eledoisin. aFGF (102-111) corresponds to amino acid residues 102-111 of the fulllength peptide.

Regorafenib (BAY 73-4506) 是一种多靶点受体酪氨酸激酶抑制剂，抑制 RET、C-RAF、VEGFR2、c-Kit、VEGFR1 和 PDGFRβ (IC50=1.5/2.5/4.2/7/13/22 nM)，具有口服活性。Regorafenib 具有抗肿瘤和抗血管生成活性。

SU4984 是蛋白质酪氨酸激酶抑制剂，能够抑制成纤维细胞生长因子受体 1 (FGFR1) (IC50:10-20 μM)，还能够抑制血小板衍生的生长因子受体和胰岛素受体的活性。它可用于研究癌症。

FGFR1/DDR2 inhibitor 1 是一种具有口服活性的成纤维细胞生长因子受体 1 和盘状蛋白域受体 2 的抑制剂，能够抑制 FGFR1 (IC50:31.1 nM) 和 DDR2 (IC50:3.2 nM)，具有抗肿瘤作用。

Rogaratinib (BAY1163877) 选择性抑制成纤维细胞生长因子受体。

BW710 是一种口服活性的成纤维细胞生长因子受体 2 (FGFR2) 抑制剂，具有强效和选择性。其在抑制 BaF3-FGFR2 细胞增殖中的 IC50 为 2.8 nM，能够完全抑制 FGFR2 的酶活性。BW710 选择性地作用于包括 FGFR1、FGFR3 和 FGFR4 在内的其他 75 种酪氨酸激酶，且对 FGFR2 信号传导及其驱动的癌细胞增殖有明显抑制作用。BW710 药代动力学表现优良，在小鼠中口服生物利用度达到 29%。

Sirtuinmodulator 8 是一种沉默调节蛋白 (sirtuin) 的调节剂，能够激活 Sirtuin 的活性。它显著下调单核细胞趋化蛋白-1 (MCP-1) 的表达，并上调成纤维细胞生长因子 21 (FGF21) 的表达。同时，Sirtuinmodulator 8 可调控与炎症和代谢相关的基因表达，展现出在代谢性疾病 (如糖尿病、肥胖) 及炎症性疾病研究中的潜力。

PD-161570 是一种有效的 ATP 竞争性人 FGF-1 受体抑制剂，IC50 为 39.9 nM，Ki 为 42 nM。它还是骨形态发生蛋白 (BMPs) 和TGF-β信号抑制剂。它抑制PDGF 刺激的自磷酸化和FGF-1受体磷酸化，IC50分别为 450 和 622 nM。它抑制 PDGFR、EGFR 和 c-Src 酪氨酸激酶，IC50 值分别为 310、240 和 44 nM。

AS1069562 is an inhibitor of serotonin (5-HT) and norepinephrine (NE) reuptake which acts by notably restoring reduced insulin-like growth factor 1 and fibroblast growth factor 2 mRNA levels in dorsal root ganglion and spinal cord, respectively.

FIIN-3 是FGFR 的不可逆抑制剂，对FGFR1、FGFR2、FGFR3和FGFR4的IC50值分别为13.1、21、31.4和35.3 nM。

PRLX-93936是一种选择性的Ras通路蛋白抑制剂，能够调节RAS/JNK通路相关蛋白磷酸化，诱导caspase依赖性细胞凋亡和细胞周期阻滞，具有抗癌活性。

Picropodophyllotoxin (AXL 1717) 是一种环木脂素生物碱，存在于五月树(Podophyllum peltatum) 中，是一种具有潜在抗肿瘤活性的胰岛素样生长因子 1 受体 (IGF1R) 的小分子抑制剂。它特异性抑制 IGF1R 的活性并下调细胞表达，而不干扰其他生长因子受体的活性，例如胰岛素受体、表皮生长因子、血小板衍生生长因子、成纤维细胞生长因子和肥大/干细胞生长因子 (KIT) ）。该药剂在抑制肿瘤细胞增殖和诱导肿瘤细胞凋亡方面显示出有效的活性。 IGF1R 是一种在多种人类癌症中过度表达的受体酪氨酸激酶，在多种癌细胞的生长和存活中起关键作用。

Ferulic acid acyl-β-D-glucoside, a metabolite of Ferulic Acid, is a novel inhibitor of fibroblast growth factor receptor 1 (FGFR1). It exhibits IC50 values of 3.78 µM and 12.5 µM for FGFR1 and FGFR2, respectively.

Futibatinib（TAS-120） 是口服具有活力的、选择性强的、高生物利用度的、不可逆的 FGFR 抑制剂，对 FGFR1、FGFR2、FGFR3 和 FGFR4 的 IC50 值分别为 3.9、1.3、1.6 和 8.3 nM。[2]

Tyrosine kinase-IN-1是一种多靶点酪氨酸激酶抑制剂，能够抑制KDR (IC50:4 nM)，Flt-1 (IC50:20 nM)，FGFR1 (IC50:4 nM) 和 PDGFRα (IC50:2 nM)。

FGFR-IN-3 (compound 6) is a highly potent and orally active modulator of FGFR (fibroblast growth factor receptor). It has the ability to penetrate the blood-brain barrier (BBB). Additionally, FGFR-IN-3 exhibits significant neuroprotective properties. Therefore, it holds potential for research on neurodegenerative diseases [1].

SUN13837 is an orally active, potent modulator of the fibroblast growth factor receptor (FGFR) with the ability to penetrate the blood-brain barrier (BBB). It exhibits neuroprotective activity and holds promise for furthering research on neurodegenerative diseases [1].

CPL304110 是一种口服具有活力的、选择性的、有效的成纤维细胞生长因子受体 FGFR (1-3) 的抑制剂，能够作用于 FGFR1 (IC50: 0.75 nM)、 FGFR2 (IC50: 0.5 nM)、FGFR3 (IC50: 3.05 nM) 。

Dovitinib 是一种口服有效的、多靶点的酪氨酸激酶 (RTK) 抑制剂，具有抗肿瘤作用。

FGFR3-IN-1 (compound 1) 是一种成纤维细胞生长因子受体 (FGFR) 抑制剂，可抑制FGFR1 (IC50: 40 nM)，FGFR2 (IC50: 5.1 nM) 和 FGFR3 (IC50: 12 nM)。FGFR3-IN-1 能够用于研究膀胱癌。

The growth factors, platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF) play major roles in enhanced smooth muscle cells growth in rodent blood vessels after vascular injury. Tyrosine kinase inhibition has been shown to be effective in blocking tyrosine phosphorylation at the PDGF and bFGF receptors in cultured fibroblast and vascular smooth muscle cells which in turn inhibits their proliferation[1]. CGP 53716 is a specific PDGFR tyrosine kinase inhibitor on SMC (smooth muscle cell) proliferation and migration in vitro and in neointimal formationin vivo[3]. CGP 53716 inhibited serum-induced cell growth in RASMC (rat aortic smooth muscle cells). And it completely blocked PDGF-BB tyrosine receptor autophosphorylation in RASMC and 3T3 cells, PDGF-BB-induced phosphorylation of mitogen-activated protein kinase at 1 μM in RASMC and inhibited PDGF-BB-induced c-Fos protein expression at 1 μM in RASMC; consistent with inhibition of PDGF-BB-induced DNA synthesis. Further, CGP 53716 inhibited PDGF-BB-, bFGF- and EGF-induced DNA synthesis in a concentration-dependent manner in each cell line. And it showed a 2- to 4-fold selectivity for PDGF-BB-stimulated DNA synthesis over bFGF or EGF in RASMC or 3T3 cells[1]. CGP 53716 inhibited dose dependently tyrosine phosphorylation of both the known PDGFRs: the PDGFR-α and PDGFR-β. After rat carotid artery ballooning injuryin vivo, the migration of alpha-actin-positive cells on the luminal side of internal elastic lamina was decreased with 50 mg/kg/day of CGP 53716 from 38 ± 10 (control group) to 4 ± 2. Intima/media ratio was inhibited by 40% after 14 days in the CGP 53716-treated group (P=0.028) after rat aortic denudation[3].